Summary by Moomoo AI
On January 23, 2024, Johnson & Johnson reported its financial results for the fourth quarter and the full year ended December 31, 2023. The company announced a 7.3% increase in fourth-quarter sales, reaching $21.4 billion, with an operational growth of 7.2% and an adjusted operational growth of 5.7%. Excluding the COVID-19 vaccine, the operational growth was 10.9%. Fourth-quarter earnings per share (EPS) rose by 39.3% to $1.70, and adjusted EPS increased by 11.7% to $2.29. For the full year, Johnson & Johnson saw a 6.5% increase in sales to $85.2 billion, with operational growth of 7.4% and adjusted operational growth of 5.9%. The full-year EPS decreased by 15.3% to $5.20 due to a special one-time charge in the first quarter, while the adjusted EPS grew by 11.1% to $9.92. The company confirmed its 2024 guidance, projecting operational sales growth of 5.0% - 6.0% and an adjusted operational EPS of $10.55 - $10.75, indicating a mid-point growth of 7.4%. Joaquin Duato, Chairman and CEO, expressed confidence in the company's ability to lead health innovation. The report also highlighted regulatory approvals, product launches, and research advancements in various healthcare segments.